Covid-19 vaccines

Abingworth Achieves Financial Close, Raises USD 582 Million Abingworth, a London-based venture capital firm, has announced the closing of its new Clinical Co-Development Fund 2 (ACCD 2) worth USD 582 million, however, the fund was aiming to gather USD $350 million.  Not long ago, the company also closed ...

Ocugen-Bharat Biotech’s Covaxin Shows Efficacy Against B.1.617 Variant With the COVID-19 cases exponentially increasing, there is a worrisome climate all over the world. Physicians, doctors, researchers, the whole healthcare and pharmaceutical industry are at their toes fighting the second wave of the coronaviru...

Promega Biotech Ibérica Gains Recognition for COVID-19 Response in Spain Promega Biotech Ibérica has been heralded as the business leader in Spain for its COVID-19 response. The company’s innovative approach to deal with COVID-19 and pandemic has led La Razón, a daily newspaper based in Madrid, to felicitate the...

Hot on the heels, Aurinia launches its drug in the Lupus market after GSK Aurinia Pharmaceuticals has recently got the USFDA approval for its Lupkynis (voclosporin) in combination with a background immunosuppressive therapy regimen to treat adult patients with active Lupus nephritis (LN). Lupkynis is the first o...

Gannex received US FDA fast track designation for its NASH drug, ASC42 an FXR Agonist Gannex Pharma has received Fast Track designation approval from FDA for its drug candidate ASC42 for non-alcoholic steatohepatitis (NASH). The FTA designation will help the pharma company to advance its research and development...

KaliVir, Astellas Pharma forms a licensing deal for VET2-L2 oncolytic virus KaliVir Immunotherapeutics and Astellas Pharma entered into a worldwide exclusive licensing agreement for the development, research, and commercialization of VET2-L2 to widen the horizon of therapeutic approaches available in the Immuno-...

Albireo Pharma Hopeful to Commercialize its PFIC Treatment by the End of the Year Albireo Pharma, spun out of AstraZeneca, has long been working on developing potential and efficient treatment drugs for the patients suffering from progressive familial intrahepatic cholestasis (PFIC), a rare disorder that leads t...

Pfizer's COVID-19 vaccine heralded as the showstopper with over 90% effectiveness  Based on the interim data from the Phase III COVID-19 vaccine trial results, the pharma titan, Pfizer, announced that its COVID-19 vaccine is more than 90% effective in preventing coronavirus infection. Tedros Adhanom Ghebrey...

Inovio’s shares plunge after FDA holds-off its COVID-19 vaccine Phase II/III trial  Inovio’s COVID-19 vaccine, INO-4800, Phase II/III clinical trials’ have been put under partial hold after the USFDA raised questions. The firm mentioned the reason behind the halt of the trials is not due to adverse events i...

AstraZeneca/ Oxford resumes the trial of their COVID-19 vaccine in the UK After receiving a go-ahead from the UK’s Medicines Health Regulatory Authority, AstraZeneca and the University of Oxford have resumed the trials of their experimental coronavirus candidate AZD1222 in the country. A rapid review by the tria...